clinical trial · NCT07213960
A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis
FSGSAPL2Placebo
brief summary
This is a sequential phase 2/3 study to evaluate the efficacy and safety of twice-weekly subcutaneous (SC) infusions of APL2 in patients diagnosed with FSGS. The initial phase 2 portion is a single-arm, open-label study in adults diagnosed with FSGS. Phase 2 will commence prior to randomizing for phase 3. The phase 3 portion of the study is a randomized, placebo-controlled, double-blinded, multicenter study in adults and adolescents diagnosed with FSGS.
started
Dec 1, 2025
primary completion
Oct 1, 2029
completion
Dec 1, 2029
last updated
Oct 9, 2025
official title
A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of APL2 in Adults and Adolescents With Focal Segmental Glomerulosclerosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol